Lead Pharma, a developer of medicines for the treatment of immunological and oncological indications, has achieved a third milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment.   The collaboration aims to develop small molecules for the treatment of a broad range of autoimmune disorders, including common diseases such as psoriasis, rheumatoid arthritis and inflammatory bowel disease.   The partnership originated in 2015, when Lead Ph...